<DOC>
	<DOCNO>NCT00000764</DOCNO>
	<brief_summary>PRIMARY : In Phase I , define broadly tolerable dose isotretinoin use combination interferon alfa-2a ( IFN alfa-2a ) . In Phase II , determine trend efficacy isotretinoin alone combination IFN alfa-2a chemoprevention ( prevent progression recurrence ) anal intraepithelial neoplasia ( AIN ) / squamous intraepithelial lesion ( SIL ) patient HIV infection . SECONDARY : To evaluate effect isotretinoin alone combination IFN alfa-2a immune function marker , human papillomavirus ( HPV ) type , HPV DNA level . Patients HIV infection significant risk recurrence follow local ablation intraepithelial neoplasia ; thus , anogenital epithelial may become increasingly important cause morbidity , possibly mortality , HIV epidemic matures . Clinical study non-HIV-infected subject establish synthetic retinoids inhibit progression epithelial preneoplastic condition neoplastic state .</brief_summary>
	<brief_title>Chemoprevention Anal Neoplasia Arising Secondary Anogenital Human Papillomavirus Infection Persons With HIV Infection .</brief_title>
	<detailed_description>Patients HIV infection significant risk recurrence follow local ablation intraepithelial neoplasia ; thus , anogenital epithelial may become increasingly important cause morbidity , possibly mortality , HIV epidemic matures . Clinical study non-HIV-infected subject establish synthetic retinoids inhibit progression epithelial preneoplastic condition neoplastic state . In Phase I portion study , 20 patient per site receive isotretinoin escalating dos . If patient experience grade 2 bad toxicity ( grade 3 bad hypertriglyceridemia ) , dose reduce previously tolerate dose remainder 6 week period . Patients reassess anal neoplasia ; progression grade 2 bad toxicity receive additional 6 week isotretinoin combination interferon alfa-2a . For Phase II study , separate group patient undergone ablative therapy randomize one three arm ( 26 patients/arm ) : isotretinoin alone dose tolerate least 60 percent patient Phase I ; isotretinoin plus interferon alfa-2a ; observation . Treatment continue 48 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis ( required patient CD4 count &lt; 200 cells/mm3 ) . Chemoprophylaxis candidiasis herpes simplex . Metronidazole 14 day . Erythropoietin . Patients must : HIV seropositivity . NO active opportunistic infection require treatment prohibit drug . Phase I Current grade 1 AIN ( i.e. , low grade SIL ) OR treat untreated grade 2 3 AIN ( i.e. , high grade SIL ) . Phase II Prior histologically confirm grade 2 3 AIN / high grade SIL , ablative therapy within past 3090 day . Capability comply study protocol . NOTE : The term condyloma , grade 1 AIN , low grade SIL interchangeable . Grade 2 3 AIN interchangeable high grade SIL . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active medical problem patient undergoing evaluation prohibit therapy require . Other active malignancy require systemic therapy . Significant symptomatic cardiac disease . NOTE : Patients malignancy manage local therapy ( e.g. , Kaposi 's sarcoma , basal cell carcinoma ) may enroll discretion site investigator . Concurrent Medication : Excluded : GCSF ( filgrastim ) . Myelosuppressive antibiotic ( except cotrimoxazole PCP prophylaxis ) . Corticosteroids . Biologic response modifier . Cytotoxic chemotherapy . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : History ventricular arrhythmia myocardial infarction . Prior Medication : Excluded within 20 day prior study entry : GCSF ( filgrastim ) . Myelosuppressive antibiotic ( except cotrimoxazole PCP prophylaxis ) . Corticosteroids . Biologic response modifier . Cytotoxic chemotherapy . Prior Treatment : Excluded within 20 day prior study entry : Radiation therapy . Excluded within 14 day prior study entry : Transfusion . Active substance abuse illegal drug use ( alcohol consumption strongly discourage ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Anus Neoplasms</keyword>
	<keyword>Papillomavirus , Human</keyword>
	<keyword>Papovaviridae Infections</keyword>
	<keyword>Tumor Virus Infections</keyword>
	<keyword>Isotretinoin</keyword>
</DOC>